|
1
|
Ferlay J, Colombet M, Soerjomataram I,
Parkin DM, Piñeros M, Znaor A and Bray F: Cancer statistics for the
year 2020: An overview. Int J Cancer. 149:778–789. 2021. View Article : Google Scholar
|
|
2
|
McPhail S, Johnson S, Greenberg D, Peake M
and Rous B: Stage at diagnosis and early mortality from cancer in
England. Br J Cancer. 112 (Suppl 1):S108–S115. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Guo F, Kuo YF, Shih YCT, Giordano SH and
Berenson AB: Trends in breast cancer mortality by stage at
diagnosis among young women in the United States. Cancer.
124:3500–3509. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Schneble EJ, Graham LJ, Shupe MP, Flynt
FL, Banks KP, Kirkpatrick AD, Nissan A, Henry L, Stojadinovic A,
Shumway NM, et al: Current approaches and challenges in early
detection of breast cancer recurrence. J Cancer. 5:281–290. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kavan S, Kruse TA, Vogsen M, Hildebrandt
MG and Thomassen M: Heterogeneity and tumor evolution reflected in
liquid biopsy in metastatic breast cancer patients: A review.
Cancer Metastasis Rev. 41:433–446. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Clatot F: Review ctDNA and Breast Cancer.
Tumor Liquid Biopsies. Schaffner F, Merlin JL and von Bubnoff N:
Springer International Publishing; Cham: pp. 231–252. 2020,
View Article : Google Scholar
|
|
7
|
Apiou F, Flagiello D, Cillo C, Malfoy B,
Poupon MF and Dutrillaux B: Fine mapping of human HOX gene
clusters. Cytogenet Cell Genet. 73:114–115. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mallo M, Wellik DM and Deschamps J: Hox
genes and regional patterning of the vertebrate body plan. Dev
Biol. 344:7–15. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gilbert PM, Mouw JK, Unger MA, Lakins JN,
Gbegnon MK, Clemmer VB, Benezra M, Licht JD, Boudreau NJ, Tsai KK,
et al: HOXA9 regulates BRCA1 expression to modulate human breast
tumor phenotype. J Clin Invest. 120:1535–1550. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhou L, Wang Y, Zhou M, Zhang Y, Wang P,
Li X, Yang J, Wang H and Ding Z: HOXA9 inhibits HIF-1α-mediated
glycolysis through interacting with CRIP2 to repress cutaneous
squamous cell carcinoma development. Nat Commun. 9:14802018.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Deaton AM and Bird A: CpG islands and the
regulation of transcription. Genes Dev. 25:1010–1022. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Constâncio V, Nunes SP, Henrique R and
Jerónimo C: DNA Methylation-Based testing in liquid biopsies as
detection and prognostic biomarkers for the four major cancer
types. Cells. 9:6242020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Faaborg L, Fredslund Andersen R, Waldstrøm
M, Høgdall E, Høgdall C, Adimi P, Jakobsen A and Dahl Steffensen K:
Analysis of HOXA9 methylated ctDNA in ovarian cancer using
sense-antisense measurement. Clin Chim Acta. 522:152–157. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Faaborg L, Jakobsen A, Waldstrøm M,
Petersen CB, Andersen RF and Steffensen KD: HOXA9-methylated DNA as
a diagnostic biomarker of ovarian malignancy. Biomark Med.
15:1309–1317. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wen SWC, Andersen RF, Rasmussen K, Thomsen
CB, Hansen TF, Nederby L, Hager H, Jakobsen A and Hilberg O:
Validating methylated HOXA9 in bronchial lavage as a diagnostic
tool in patients suspected of lung cancer. Cancers (Basel).
13:42232021. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Faaborg L, Andersen RF, Waldstrøm M,
Henriksen JR, Adimi P, Jakobsen A and Steffensen KD: Prognostic
impact of circulating methylated homeobox A9 DNA in patients
undergoing treatment for recurrent ovarian cancer. Cancers (Basel).
14:17662022. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rusan M, Andersen RF, Jakobsen A and
Steffensen KD: Circulating HOXA9-methylated tumour DNA: A novel
biomarker of response to poly (ADP-ribose) polymerase inhibition in
BRCA-mutated epithelial ovarian cancer. Eur J Cancer. 125:121–129.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wen SWC, Andersen RF, Hansen TF, Nyhus CH,
Hager H, Hilberg O and Jakobsen A: The prognostic impact of
circulating homeobox A9 methylated DNA in advanced non-small cell
lung cancer. Transl Lung Cancer Res. 10:855–865. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Park SM, Choi EY, Bae M, Choi JK and Kim
YJ: A long-range interactive DNA methylation marker panel for the
promoters of HOXA9 and HOXA10 predicts survival in breast cancer
patients. Clin Epigenetics. 9:732017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
McShane LM, Altman DG, Sauerbrei W, Taube
SE, Gion M and Clark GM: REporting recommendations for tumour
MARKer prognostic studies (REMARK). Br J Cancer. 93:387–391. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tan PH, Ellis I, Allison K, Brogi E, Fox
SB, Lakhani S, Lazar AJ, Morris EA, Sahin A, Salgado R, et al: The
2019 World Health Organization classification of tumours of the
breast. Histopathology. 77:181–185. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wen SWC, Andersen RF, Petersen LMS, Hager
H, Hilberg O, Jakobsen A and Hansen TF: Comparison of mutated KRAS
and methylated HOXA9 Tumor-Specific DNA in advanced lung
adenocarcinoma. Cancers. 12:37282020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Pallisgaard N, Spindler KLG, Andersen RF,
Brandslund I and Jakobsen A: Controls to validate plasma samples
for cell free DNA quantification. Clin Chim Acta. 446:141–146.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Roperch JP, Incitti R, Forbin S, Bard F,
Mansour H, Mesli F, Baumgaertner I, Brunetti F and Sobhani I:
Aberrant methylation of NPY, PENK, and WIF1 as a promising marker
for blood-based diagnosis of colorectal cancer. BMC Cancer.
13:5662013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pedersen CA, Cao MD, Fleischer T, Rye MB,
Knappskog S, Eikesdal HP, Lønning PE, Tost J, Kristensen VN, Tessem
MB, et al: DNA methylation changes in response to neoadjuvant
chemotherapy are associated with breast cancer survival. Breast
Cancer Res. 24:432022. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cullinane C, Fleming C, O'Leary DP, Hassan
F, Kelly L, O'Sullivan MJ, Corrigan MA and Redmond HP: Association
of circulating tumor DNA with Disease-free survival in breast
cancer: A systematic review and Meta-analysis. JAMA Netw Open.
3:e20269212020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dasari A, Morris VK, Allegra CJ, Atreya C,
Benson AB III, Boland P, Chung K, Copur MS, Corcoran RB, Deming DA,
et al: ctDNA applications and integration in colorectal cancer: Aan
NCI colon and Rectal-Anal task forces whitepaper. Nat Rev Clin
Oncol. 17:757–770. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cantile M, Pettinato G, Procino A,
Feliciello I, Cindolo L and Cillo C: In vivo expression of the
whole HOX gene network in human breast cancer. Eur J Cancer.
39:257–264. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kjær IM, Kahns S, Timm S, Andersen RF,
Madsen JS, Jakobsen EH, Tabor TP, Jakobsen A and Bechmann T: Phase
II trial of delta-tocotrienol in neoadjuvant breast cancer with
evaluation of treatment response using ctDNA. Sci Rep. 13:84192023.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Merker JD, Oxnard GR, Compton C, Diehn M,
Hurley P, Lazar AJ, Lindeman N, Lockwood CM, Rai AJ, Schilsky RL,
et al: Circulating tumor DNA analysis in patients with cancer:
American society of clinical oncology and college of american
pathologists joint review. J Clin Oncol. 36:1631–1641. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Fribbens C, Garcia Murillas I, Beaney M,
Hrebien S, O'Leary B, Kilburn L, Howarth K, Epstein M, Green E, et
al: Tracking evolution of aromatase inhibitor resistance with
circulating tumour DNA analysis in metastatic breast cancer. Ann
Oncol. 29:145–153. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Diehl F, Schmidt K, Choti MA, Romans K,
Goodman S, Li M, Thornton K, Agrawal N, Sokoll L, Szabo SA, et al:
Circulating mutant DNA to assess tumor dynamics. Nat Med.
14:985–990. 2008. View Article : Google Scholar : PubMed/NCBI
|
